Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma

NCT01582776 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT01582776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 1/2
Overall status
Completed
Start date
October 3, 2012
Completion date
May 20, 2022
Enrollment
317 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

follicular and agressive (dlbcl&mcl) b-cell lymphoma patients (phase ii), follicular lymphoma patients (phase ib)